Cumberland Pharmaceuticals Inc. CPIX
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.80% | -49.66% | -48.35% | -47.58% | -23.32% |
| Total Other Revenue | 210.12% | 210.12% | -34.76% | -34.76% | -34.76% |
| Total Revenue | -23.77% | -40.53% | -47.60% | -46.89% | -23.92% |
| Cost of Revenue | -35.53% | -50.95% | -51.70% | -49.87% | -21.61% |
| Gross Profit | -21.37% | -38.34% | -46.78% | -46.26% | -24.38% |
| SG&A Expenses | -6.69% | -21.47% | -32.60% | -32.40% | -17.41% |
| Depreciation & Amortization | -44.13% | -57.15% | -44.67% | -44.35% | -21.46% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.36% | -28.45% | -34.58% | -35.11% | -18.85% |
| Operating Income | -28.85% | -42.70% | -29.95% | -23.44% | -11.27% |
| Income Before Tax | -28.13% | -38.30% | 11.95% | 11.99% | 14.10% |
| Income Tax Expenses | 235.09% | 276.75% | -167.40% | -162.52% | -156.77% |
| Earnings from Continuing Operations | -29.18% | -39.41% | 12.80% | 12.79% | 14.95% |
| Earnings from Discontinued Operations | -52.43% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.61% | 179.50% | 136.12% | -11.32% | 234.96% |
| Net Income | -125.33% | 56.23% | 69.38% | 71.75% | 61.08% |
| EBIT | -28.85% | -42.70% | -29.95% | -23.44% | -11.27% |
| EBITDA | -99.73% | -229.05% | -81.25% | -66.21% | -45.72% |
| EPS Basic | -106.49% | 58.91% | 69.92% | 71.13% | 59.86% |
| Normalized Basic EPS | 20.00% | 18.06% | 19.08% | 14.97% | -35.41% |
| EPS Diluted | -100.65% | 59.63% | 69.61% | 70.81% | 58.89% |
| Normalized Diluted EPS | 20.00% | 18.06% | 19.08% | 14.97% | -35.18% |
| Average Basic Shares Outstanding | 4.82% | 6.36% | 4.25% | 2.24% | 0.27% |
| Average Diluted Shares Outstanding | 4.82% | 6.36% | 4.25% | 2.24% | -0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |